Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary.
The post Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs appeared first on MedCity News.
